Oncolytics Biotech (ONCY) Retained Earnings (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Retained Earnings data on file, last reported at $6.2 million in Q4 2025.

• On a quarterly basis, Retained Earnings fell 80.48% year-over-year to $6.2 million in Q4 2025; TTM through Dec 2025 was $6.2 million, a 80.48% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, up 101.55% from the prior year.
• Retained Earnings for Q4 2025 stood at $6.2 million, down from $33.2 million in the prior quarter.
• Over the last five years, Retained Earnings for ONCY reached as high as $33.2 million in Q3 2025 and fell as low as $487697.3 in Q4 2022.
• Historically, Retained Earnings has averaged $27.2 million across 5 years, with a median of $30.3 million in 2022.
• Across the five-year window, Retained Earnings sank 98.2% in 2022 and jumped 6243.22% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $27.1 million in 2021, then sank by 98.2% to $487697.3 in 2022, then soared by 6243.22% to $30.9 million in 2023, then advanced by 3.07% to $31.9 million in 2024, then sank by 80.48% to $6.2 million in 2025.
• Per Business Quant data, the three most recent Retained Earnings figures were $6.2 million in Q4 2025, $33.2 million in Q3 2025, and $32.3 million in Q2 2025.